Drug Profile
CEP 431
Latest Information Update: 26 Mar 2007
Price :
$50
*
At a glance
- Originator Cephalon
- Class Neuroprotectants; Nootropics
- Mechanism of Action Serine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 26 Mar 2007 Discontinued for Alzheimer's disease in USA (SC)
- 30 May 2001 Profile reviewed but no significant changes made
- 20 Jan 1997 No-Development-Reported for Alzheimer's disease in USA (SC)